MND
"motor neuron disease" AND "amyotrophic lateral sclerosis"
motor neuron disease ALS upper lower motor neuron anatomy diagram
A medical schematic diagram illustrating the neuroanatomical pathways of upper motor neurons (UMN) and lower motor neurons (LMN) and their selective involvement in Amyotrophic Lateral Sclerosis (ALS) variants. The diagram features a lateral view of the human brain, a coronal section of the brain, and transverse sections of the spinal cord (cervical and lumbar levels). Two primary tracts are highlighted: the corticobulbar (CB) tract, represented by green solid circles (UMN) and open circles (LMN), and the corticospinal (CS) tract, represented by blue solid circles (UMN) and open circles (LMN). Solid circles represent UMN cell bodies in the motor cortex, while open circles denote LMNs in the brainstem (bulbar) and spinal cord. Colored vertical tick marks inside these circles indicate specific disease phenotypes: red for classic ALS (CS & CB UMN and LMN), black for Primary Lateral Sclerosis (PLS, UMN only), and yellow for Progressive Muscular Atrophy (PMA, LMN only). Other variants shown include Pseudobulbar palsy (CB UMN), Flail arm, and Flail leg (specific CS LMN segments). This illustration serves as an educational tool for differentiating motor neuron disease phenotypes based on the anatomical site of degeneration.
This pathophysiology diagram illustrates the dysfunctional serotonergic pathways in Parkinson's disease (PD) and Amyotrophic Lateral Sclerosis (ALS). The upper section compares cerebral mechanisms: the PD side depicts lesioned raphe nuclei (RN) and dopamine (DA) depletion leading to decreased motor cortex activity. The ALS side shows cortical involvement with projections descending toward the brainstem. The lower section detail spinal cord mechanisms, focusing on the motor neuron. It contrasts two disease progression theories: the 'Dying Forward Hypothesis,' represented by descending pathways leading to glutamate excitotoxicity and anterior horn cell degeneration; and the 'Dying Back Hypothesis,' showing retrograde pathology originating from the muscle or neuromuscular junction towards the anterior horn cell. Key components include the motor cortex (green), anterior horn cell (red circle), muscle fiber, and regulatory interneurons (excitatory and inhibitory). The diagram highlights how serotonergic loss facilitates glutamatergic excitotoxicity in ALS versus dopaminergic-serotonergic interactions in the basal ganglia of PD patients, emphasizing different anatomical sites of primary neurodegeneration.
A pathophysiology diagram illustrating the competing hypotheses for neurodegeneration in Amyotrophic Lateral Sclerosis (ALS). The illustration includes a sagittal view of the human brain and the spinal motor circuit. The 'Dying forward hypothesis' is depicted as originating in the motor cortex, showing anterograde degeneration mediated via glutamate excitotoxicity (indicated by green downward arrows). This pathway highlights the involvement of upper motor neurons and their corticofugal projections. In contrast, the 'Dying back hypothesis' is shown starting at the muscle level, suggesting retrograde degeneration caused by a deficiency of motor neurotrophic factors at the neuromuscular junction. The diagram details the lower motor neuron environment, including the anterior horn cell, excitatory and inhibitory interneurons, propriospinal neurons, and the lateral reticular nucleus. This educational graphic serves to differentiate between top-down (cortical) and bottom-up (peripheral) mechanisms of motor neuron disease progression.
This medical anatomical diagram illustrates the organization of the human corticospinal tract and the selective vulnerability of motor neuron (MN) groups in Amyotrophic Lateral Sclerosis (ALS). The diagram follows the tract's descent through four anatomical levels: the Brain (cortex), Brainstem, Spinal Cord, and Sacral Spinal Cord. The pathway begins at upper motor neurons (corticospinal neurons) and descends through the brainstem, where it exhibits decussation at the medulla oblongata before continuing as the lateral corticospinal tract. The diagram highlights three specific targets: oculomotor neurons in the brainstem (innervating skeletal muscles), lower motor neurons in the spinal cord ventral horn, and Onuf's neurons in the sacral spinal cord (innervating sphincters). A color-coding scheme distinguishes neurodegeneration patterns: neurons labeled in red (corticospinal and typical lower motor neurons) represent groups vulnerable to degeneration in ALS, while those in blue (oculomotor and Onuf's neurons) represent groups characteristically resistant to the disease. The cross-sections of the spinal cord are labeled with 'ANT' to indicate anterior orientation.
Motor Neuron Disease (MND)
Definition and Spectrum
Classification of Motor Neuron Diseases
| Subtype | Motor Neurons Affected | Key Features |
|---|---|---|
| ALS (Classic) | UMN + LMN | Amyotrophy + hyperreflexia + spasticity |
| Progressive Muscular Atrophy (PMA) | LMN only | Weakness + wasting, no UMN signs |
| Progressive Bulbar Palsy | Bulbar LMN | Jaw/face/tongue/pharynx/larynx weakness |
| Primary Lateral Sclerosis (PLS) | UMN only | Spastic weakness, hyperreflexia, Babinski signs |
| Pseudobulbar Palsy | Corticobulbar UMN | Emotional lability, dysarthria, dysphagia |
| Spinal Muscular Atrophy (SMA) | LMN (spinal) | Childhood onset; SMN gene mutations |
| Kennedy's Disease (SBMA) | LMN + androgen receptor | X-linked; gynecomastia, sensory neuropathy |
Amyotrophic Lateral Sclerosis (ALS) - The Prototype
Epidemiology
- Incidence: ~2/100,000/year; prevalence ~5-7/100,000
- Peak onset: 55-65 years (familial forms slightly younger)
- Male:female ratio ~1.5:1 in sporadic; approaches 1:1 in familial
- Bulbar onset: ~25-30% of cases; worse prognosis
- Median survival: 2-3 years; ~20% survive to 5 years; ~10% survive to 10 years
- Poor prognostic factors: bulbar onset, older age, certain genotypes (e.g., C9orf72)
Pathology
- Degeneration and loss of motor neurons with astrocytic gliosis and microglial proliferation
- UMN: Loss of Betz cells from Brodmann area 4; axonal loss in corticospinal tracts
- LMN: Loss of anterior horn cells in spinal cord and brainstem motor nuclei
- Intraneuronal inclusions: TDP-43-positive and FUS-positive ubiquitinated inclusions
- Bunina bodies: Small eosinophilic cytoplasmic inclusions (characteristic)
- Spheroids: Focal enlargements in proximal motor axons (neurofilament accumulations)
- Extramotor pathology may occur in frontotemporal cortex, hippocampus, thalamus, substantia nigra
Clinical Features
Upper Motor Neuron Signs
- Spasticity, hyperreflexia
- Pseudobulbar affect (emotional lability)
- Babinski sign
- Slow, spastic dysarthria
- Jaw jerk (brisk)
Lower Motor Neuron Signs
- Muscle weakness and wasting (amyotrophy)
- Fasciculations (visible twitching under skin)
- Hyporeflexia (in pure LMN areas)
- Flaccid dysarthria, dysphagia, dysphonia (bulbar)
- Cramps
Key Features
- No sensory involvement (sensory pathways are spared)
- No autonomic dysfunction (bladder/bowel intact until very late)
- No eye movement disorder (oculomotor nuclei spared)
- Cognitive changes: ~15% develop frank FTD; up to 50% have subtle frontal deficits
Genetics
| Gene | Inheritance | % of FALS | Mechanism |
|---|---|---|---|
| C9orf72 | AD | ~40% of FALS; ~7% sporadic | Hexanucleotide (GGGGCC) repeat expansion; RNA toxicity, nucleocytoplasmic transport defect |
| SOD1 | AD (mostly), AR | 15-20% of FALS | Toxic gain-of-function; oxidative stress, protein aggregation |
| TDP-43 (TARDBP) | AD | ~4% | RNA processing defects; nuclear-to-cytoplasmic mislocalization |
| FUS/TLS | AD | ~4% | RNA processing; nuclear-cytoplasmic shuttling disruption |
| UBQLN2 | X-linked | Rare | Ubiquitin-proteasome pathway |
Pathogenesis
- Protein instability / degradation failure - mutant SOD1, ubiquitin; protein aggregation
- RNA processing defects - C9orf72 (hexanucleotide repeat RNA foci, toxic dipeptides), TDP-43, FUS/TLS
- Axonal cytoskeleton and transport failure - dynactin, profilin-1
- Glutamate excitotoxicity ("dying forward" hypothesis - cortical origin via glutamate release)
- Oxidative stress
- Mitochondrial dysfunction
- Neuroinflammation: Activated microglia and astrocytes accelerate disease
- Defective autophagy
- Neuromuscular junction failure ("dying back" hypothesis - peripheral origin)
Diagnosis
| Category | Criteria |
|---|---|
| Definite ALS | UMN + LMN signs in ≥3 regions |
| Probable ALS | UMN + LMN signs in 2 regions, some UMN rostral to LMN |
| Probable ALS, lab-supported | UMN + LMN in 1 region, UMN alone in another + EMG LMN involvement in ≥2 limbs |
| Possible ALS | UMN + LMN in 1 region only; or UMN alone in ≥2 regions; or LMN rostral to UMN |
| Familial ALS | UMN or LMN signs in ≥1 region + disease-causing gene mutation |
Key Investigations
- EMG/NCS: Denervation (fibrillations, positive sharp waves, fasciculation potentials) in multiple regions; nerve conduction normal (distinguishes from neuropathy)
- MRI brain & spine: Exclude structural causes (spondylosis, Chiari malformation, tumors, AVM)
- Pulmonary function: FVC (erect and supine), MIP, sniff nasal pressure - supine FVC is more sensitive for diaphragmatic weakness
- CSF: Exclude inflammatory/infectious causes
- Genetic testing: SOD1, C9orf72, TDP-43, FUS panel
- Serum: Heavy metals, anti-GM1 antibodies, HTLV-1 titer, paraprotein screen
Mimics to Exclude
| Category | Examples |
|---|---|
| Structural | Cervical spondylosis, foramen magnum tumor, Chiari malformation, syrinx |
| Infectious | Polio, Lyme, HIV myelopathy, HTLV-1 |
| Toxic/metabolic | Lead, aluminum, strychnine |
| Immunologic | Motor neuropathy with conduction block, plasma cell dyscrasia |
| Genetic | Kennedy's disease, adult Tay-Sachs, hexosaminidase-A deficiency |
Treatment
Disease-Modifying Drugs
| Drug | Mechanism | Effect |
|---|---|---|
| Riluzole 100 mg/day | Reduces glutamate excitotoxicity (diminishes glutamate release) | ~2-3 months survival extension; first approved drug |
| Edaravone | Antioxidant (free radical scavenger) | Modest slowing of disability progression (IV or oral) |
| Tofersen (ASO) | Antisense oligonucleotide targeting SOD1 mRNA; intrathecal delivery | FDA approved for SOD1-mediated ALS; reduces SOD1 protein |
Supportive and Rehabilitative Care
- Respiratory: Non-invasive positive pressure ventilation (NIPPV) for hypoventilation; cough-assist device prevents aspiration pneumonia; tracheostomy for long-term ventilation
- Nutritional: Gastrostomy (PEG) when dysphagia impairs nutrition - ideally placed while FVC >50%
- Communication: Speech synthesizers, augmentative/alternative communication devices
- Mobility: Foot-drop splints, finger-extension splints, wheelchair
- Multidisciplinary ALS clinic: Neurologist, physiotherapist, occupational therapist, speech therapist, respiratory physician, nutritionist, palliative care
- Palliative/Hospice: End-of-life planning, symptom management (pain, secretions, anxiety), hospice care affirms dignity and independence
Other MND Variants
- Kennedy's Disease (X-SBMA): X-linked; CAG repeat expansion in androgen receptor gene; LMN only + androgen insensitivity (gynecomastia, reduced fertility); no UMN signs; subtle sensory neuropathy distinguishes from ALS
- Spinal Muscular Atrophy (SMA): SMN gene mutations; types I-IV; autosomal recessive; childhood onset (SMA I = Werdnig-Hoffmann); LMN only
- ALS-FTD Overlap: ~15% of ALS; degeneration of frontotemporal neurons; most commonly associated with C9orf72 expansion
- Western Pacific ALS (ALS-PDC): Guam/Marianas; ALS-Parkinsonism-Dementia complex; declining incidence; proposed environmental trigger
Summary Points
- MND = group of disorders; ALS = classic form with combined UMN + LMN involvement
- ALS is relentlessly progressive and almost universally fatal; median survival 2-3 years
- TDP-43 inclusions are the pathological hallmark of sporadic ALS; Bunina bodies are classic
- C9orf72 hexanucleotide expansion is the single most common genetic cause (~40% FALS)
- Riluzole, edaravone, and tofersen (SOD1-ALS) are the currently approved disease-modifying agents
- Management is multidisciplinary, focusing on maintaining function, respiratory support, nutrition, and quality of life
- Always exclude treatable mimics (cervical myelopathy, conduction block neuropathy, inflammatory disorders)